论文部分内容阅读
多廿烷醇是一种含有8种长链脂肪伯醇的生物制剂,是由古巴甘蔗蜡经有机溶剂特殊处理,进行皂化后提纯得到,多廿烷醇通过抑制胆固醇的生物合成发挥作用,其独特的作用机制为调脂治疗带来新靶点[1],且其品质多效,具有良好的临床应用前景,现对其在临床上的应用进展进行综述。1多廿烷醇可有效降脂众所周知,血脂异常是引起糖尿病、心脑血管病死亡的首要危险因素。多廿烷醇作为一种降脂药物,其临床有效性、安全性和耐受性已经为多个随机、双肓及安慰剂对照临床研究证实[2],多廿烷醇可抑制胆固醇合成及提高低密度脂蛋白
Policosanol is a kind of biological preparation containing 8 kinds of long-chain fatty primary alcohols, which is obtained from Cuban sugar cane wax by special treatment with organic solvent and saponification and purification. Policosanol plays a role in inhibiting the biosynthesis of cholesterol. The unique mechanism of action for the lipid-lowering therapy to bring new targets [1], and its quality and more effective, has good clinical application prospects, is its clinical application of the progress are reviewed. 1 policosanol can be effective lipid-lowering It is well-known that dyslipidemia is the leading risk factor for diabetes and cardiovascular and cerebrovascular diseases. Policosanol, as a lipid-lowering drug, has been clinically proven in multiple randomized, double-blind, and placebo-controlled clinical trials [2]. Policosanol inhibits cholesterol synthesis and Increase LDL